Guido Oelkers, Sobi CEO
Sobi swoops in with $1.7B buyout for a biotech with an approved JAK inhibitor, but low on cash
Sobi, the Swedish pharma specializing in rare diseases, is joining the M&A party with a $1.7 billion buyout of CTI BioPharma.
The crown jewel of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
